Goldman Sachs cuts Incyte to hold, cites Jakafi outlook uncertainty (INCY)

undefined undefined

Goldman Sachs has downgraded Incyte (NASDAQ:INCY) to neutral, citing continued uncertainty around the lifecycle management of the company’s drug Jakafi ahead of its expected loss of market exclusivity in the EU in mid-2027 and the US in late 2028.


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *